Associations - BRAF mutation

BIOMARKER:

BRAF mutation

Entrez ID:

673

Related biomarkers:

‹

›

BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials Eur J Cancer - 3 weeks PD-L1 inhibitor Sensitive : C3 Eur J Cancer - 3wk
BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials Eur J Cancer - 3 weeks PD1 inhibitor Sensitive : C3 Eur J Cancer - 3wk
BRAF mutation BRAF mutation	Melanoma Melanoma	dabrafenib + granisetron intravenous Sensitive: A2 - Guideline dabrafenib + granisetron intravenous Sensitive : A2
BRAF mutation BRAF mutation	Colorectal Cancer CRC	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
BRAF mutation BRAF mutation	Colorectal Cancer CRC	ziv-aflibercept IV Sensitive: B - Late Trials ziv-aflibercept IV Sensitive : B
BRAF mutation BRAF mutation	Colorectal Cancer CRC	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
BRAF mutation BRAF mutation	Colorectal Cancer CRC	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
BRAF mutation BRAF mutation	Colorectal Cancer CRC	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
BRAF mutation BRAF mutation	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
BRAF mutation BRAF mutation	Colorectal Cancer CRC	FOLFIRI + cetuximab Sensitive: B - Late Trials FOLFIRI + cetuximab Sensitive : B
BRAF mutation BRAF mutation	Acute Myelogenous Leukemia AML	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
BRAF mutation BRAF mutation	Melanoma Melanoma	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
BRAF mutation BRAF mutation	Melanoma Melanoma	ipilimumab Sensitive: B - Late Trials ipilimumab Sensitive : B
BRAF mutation BRAF mutation	Colorectal Cancer CRC	panitumumab Sensitive: C2 – Inclusion Criteria panitumumab Sensitive : C2
BRAF mutation BRAF mutation	Melanoma Melanoma	binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria binimetinib + encorafenib Sensitive : C2
BRAF mutation BRAF mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
BRAF mutation BRAF mutation	Melanoma Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
BRAF mutation BRAF mutation	Melanoma Melanoma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
BRAF mutation BRAF mutation	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib Sensitive : C2
BRAF mutation BRAF mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria atezolizumab + cobimetinib Sensitive : C2
BRAF mutation BRAF mutation	Colon Cancer Colon Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
BRAF mutation BRAF mutation	Melanoma Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
BRAF mutation BRAF mutation	Melanoma Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
BRAF mutation BRAF mutation	Ovarian Cancer Ovarian Cancer	PLX8394 Sensitive: C3 – Early Trials PLX8394 Sensitive : C3
BRAF mutation BRAF mutation	Melanoma Melanoma	dabrafenib + KRT-232 Sensitive: C3 – Early Trials dabrafenib + KRT-232 Sensitive : C3
BRAF mutation BRAF mutation	Melanoma Melanoma	trametinib + dabrafenib + durvalumab Sensitive: C3 – Early Trials trametinib + dabrafenib + durvalumab Sensitive : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES